GILEAD SCIENCES INC (GILD)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for GILD
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| GILD | Chief Commercial and Corporate Affairs Officer | 56 | ["Central to Gilead\u2019s portfolio diversification", "Orchestrated the historic launch of a novel, long-acting option for HIV prevention", "Led the rapid launch and global access efforts for Gilead\u2019s COVID-19 antiviral", "Champion of responsible, ethical use of artificial intelligence", "Passionate advocate for transformational healthcare", "Led successful U.S. launch of Yeztugo for HIV prevention", "Achieved >85% U.S. payer access ahead of schedule", "Secured partnerships with the Global Fund and U.S. State Department", "Oversaw Phase 3 clinical trials of Trodelvy"] | ["Arcus Biosciences", "Neurocrine Biosciences", "University of Southern California\u2019s Leonard D. Schaeffer Center for Health Policy and Economics"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RCUS | Director | 56 | [] | [] | 2026 |
| NBIX | ["Commercial Strategy/Market Access","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Executive Leadership","Human Capital Management"] | ["Audit","Compensation","Nominating /Corporate Governance","Science and Medical Technology"] | 2026 |